Livionex, recently announced a successful end-of-Phase 2 meeting with the FDA, supporting the advancement of C-KAD, a 2.6% EDTA ophthalmic solution, to a Phase 3 clinical study. In an interview with ...
According to Dr. Masih Ahmed from Baylor College of Medicine, living in the sunny south puts us at risk of cataracts too.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback